Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 347 KB, PDF-dokument
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical and Experimental Allergy |
Vol/bind | 53 |
Udgave nummer | 12 |
Sider (fra-til) | 1318-1321 |
ISSN | 0954-7894 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
Katrine Baumann was supported by the BRIDGE—Translational Excellence Programme ( bridge.ku.dk ) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation. Grant agreement no. NNF20SA0064340 (2021 fellows). This study benefitted from the GALEN network of Urticaria Centers of Reference and Excellence (UCAREs, https://ga2len‐ucare.com/ ). 2
ID: 373887988